TransCode Therapeutics (Nasdaq:RNAZ) - Aandelenkoers, Nieuws & Analyse

RNAZ Overzicht aandelen

TransCode Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van geneesmiddelen en diagnostica voor de behandeling en identificatie van kanker.

Over het bedrijf

RNAZ fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 75.45% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $8M )

De winst is de afgelopen 5 jaar met 45.3% per jaar gedaald

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

+ 1 meer risico

TransCode Therapeutics, Inc. Concurrenten

Edesa Biotech

NasdaqCM:EDSA

US$8.7m

Cardio Diagnostics Holdings

NasdaqCM:CDIO

US$11.0m

Soligenix

NasdaqCM:SNGX

US$8.3m

Aptorum Group

NasdaqCM:APM

US$7.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor TransCode Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.47
52 Week Hoogtepunt	US$18.66
52 Week Laag	US$0.22
Bèta	0.63
11 maand verandering	-2.76%
3 maanden verandering	79.49%
1 Jaar Verandering	-96.61%
33 jaar verandering	-99.98%
5 jaar verandering	n/a
Verandering sinds IPO	-99.99%

Recent nieuws en updates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

Rendement voor aandeelhouders

	RNAZ	US Biotechs	US Markt
7D	0.9%	1.6%	2.3%
1Y	-96.6%	23.6%	35.1%

Rendement versus industrie: RNAZ presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 23.6 % opleverde.

Rendement versus markt: RNAZ presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 35.1 % opleverde.

Prijsvolatiliteit

Is RNAZ's price volatile compared to industry and market?
RNAZ volatility
RNAZ Average Weekly Movement	26.9%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van RNAZ is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 27% ) van RNAZ is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	10	Tom Fitzgerald	www.transcodetherapeutics.com

TransCode Therapeutics, Inc, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van geneesmiddelen en diagnostica voor de behandeling en identificatie van kanker. De belangrijkste therapeutische kandidaat van het bedrijf bestaat uit TTX-MC138 dat gericht is tegen microRNA-10b, een hoofdregulator van metastatische levensvatbaarheid van cellen in verschillende kankers, waaronder borstkanker, alvleesklierkanker, eierstokkanker, darmkanker en glioblastomen. De preklinische programma's omvatten TTX-siPDL1, een siRNA-gebaseerde modulator van geprogrammeerd dood-ligand 1 en twee indicatie agnostische programma's; TTX-RIGA, een RNA-gebaseerde agonist van het retinoïnezuur-induceerbare gen I gericht op activering van aangeboren immuniteit in de tumormicro-omgeving; TTX-CRISPR, een CRISPR/Cas9-gebaseerd therapieplatform voor het repareren of elimineren van kankerverwekkende genen in tumorcellen; en TTX-mRNA, een mRNA-gebaseerd platform voor de ontwikkeling van kankervaccins die cytotoxische immuunreacties tegen tumorcellen activeren.

TransCode Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van TransCode Therapeutics zich tot de beurswaarde?
RNAZ fundamentele statistieken
Marktkapitalisatie	US$8.10m
Inkomsten(TTM)	-US$17.91m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is RNAZ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RNAZ resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$17.91m
Inkomsten	-US$17.91m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.04
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde RNAZ op de lange termijn?

Bekijk historische prestaties en vergelijking

RNAZ Overzicht aandelen

Beloningen

Risicoanalyse

TransCode Therapeutics, Inc. Concurrenten

NasdaqCM:EDSA

US$8.7m

NasdaqCM:CDIO

US$11.0m

NasdaqCM:SNGX

US$8.3m

NasdaqCM:APM

US$7.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

Recent updates

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

TransCode Therapeutics, Inc. Samenvatting

0.0x

-0.5x

Inkomsten en omzet